Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials

Hofer, Silvia; Elandt, Katarzyna; Greil, Richard; Hottinger, Andreas F; Huber, Urs; Lemke, Dieter; Marosi, Christine; Ochsenbein, Adrian; Pichler, Josef; Roelcke, Ulrich; Weder, Patrik; Zander, Thilo; Wick, Wolfgang; Weller, Michael (2011). Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta oncologica, 50(5), pp. 630-5. Stockholm: Acta Oncologica 10.3109/0284186X.2011.572913

Full text not available from this repository. (Request a copy)

Patients with recurrent high-grade glioma (HGG) have a poor prognosis and there is no defined standard of care. High levels of vascular endothelial growth factor (VEGF) expressed in HGG make the anti-VEGF monoclonal antibody bevacizumab (BEV) of particular interest.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Ochsenbein, Adrian

ISSN:

0284-186X

Publisher:

Acta Oncologica

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:20

Last Modified:

17 Mar 2015 19:26

Publisher DOI:

10.3109/0284186X.2011.572913

PubMed ID:

21495907

Web of Science ID:

000290631600003

URI:

https://boris.unibe.ch/id/eprint/6460 (FactScience: 211426)

Actions (login required)

Edit item Edit item
Provide Feedback